Real-World Treatment Patterns and Outcomes of Advanced Renal Cell Carcinoma (aRCC) Patients Receiving Nivolumab+Ipilimumab or Pembrolizumab+Lenvatinib in U.S. Oncology Practice.
In: Medical Letter on the CDC & FDA, 2024-04-19, S. 836-836
serialPeriodical
Zugriff:
This document provides information about a clinical trial titled "Real-World Outcomes of Nivolumab+Ipilimumab and Pembrolizumab+Lenvatinib Among US Advanced Renal Cell Carcinoma (aRCC) Patients." The trial aims to observe and describe the characteristics, treatment patterns, and outcomes of patients with advanced Renal Cell Carcinoma (aRCC) who are receiving either Nivolumab + Ipilimumab or Pembrolizumab + Lenvatinib combination therapy. The trial is currently recruiting participants and is expected to be completed by December 31, 2024. The responsible party for the trial is Bristol-Myers Squibb. [Extracted from the article]
Copyright of Medical Letter on the CDC & FDA is the property of NewsRx and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
Titel: |
Real-World Treatment Patterns and Outcomes of Advanced Renal Cell Carcinoma (aRCC) Patients Receiving Nivolumab+Ipilimumab or Pembrolizumab+Lenvatinib in U.S. Oncology Practice.
|
---|---|
Zeitschrift: | Medical Letter on the CDC & FDA, 2024-04-19, S. 836-836 |
Veröffentlichung: | 2024 |
Medientyp: | serialPeriodical |
ISSN: | 1532-4648 (print) |
Sonstiges: |
|